Erratum: Assessment of hepatocellular carcinoma risk based on peg-interferon plus ribavirin treatment experience in this new era of highly effective oral antiviral drugs: Erratum.

[This corrects the article DOI: 10.1097/MD.0000000000005321.].

In the article “Assessment of hepatocellular carcinoma risk based on peg-interferon plus ribavirin treatment experience in this new era of highly effective oral antiviral drugs”,[ which appeared in Volume 96, Issue 1 of Medicine, an acknowledgment read “This study was supported by an Inha University Hospital grant”. The statement should have read “This study was supported by an Inha University Research grant”.